#1 Clinical Trials Search in Europe

Carfilzomib

Carfilzomib, also known by its brand name Kyprolis, is an innovative drug being studied in clinical trials for the treatment of multiple myeloma and other cancers. This article explores the use of carfilzomib in various clinical trials, examining its efficacy, safety, and potential benefits for patients with different types of cancer and varying degrees of organ function.

Table of Contents

What is Carfilzomib?

Carfilzomib is a medication used to treat multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It is also known by the brand name Kyprolis and was previously referred to as PR-171 or PR171 during its development.[1] Carfilzomib is typically used when multiple myeloma has returned (relapsed) or is not responding (refractory) to other treatments.[2]

How Carfilzomib Works

Carfilzomib belongs to a class of drugs called proteasome inhibitors. It works by blocking the proteasome, which is a structure in cells that breaks down proteins that are no longer useful. When the proteasome is turned off by carfilzomib, useless proteins build up in cancer cells, causing them to die. This effect is especially strong in myeloma cells because they produce a lot of protein and rely heavily on the proteasome to survive.[3]

Conditions Treated with Carfilzomib

Carfilzomib is primarily used to treat:

  • Multiple Myeloma: This is the main condition for which carfilzomib is prescribed.
  • Relapsed Multiple Myeloma: When the cancer has returned after previous treatment.
  • Refractory Multiple Myeloma: When the cancer is not responding to other treatments.

It is typically used in patients who have already tried other treatments, including drugs like bortezomib, thalidomide, or lenalidomide.[1]

How Carfilzomib is Administered

Carfilzomib is given as an intravenous (IV) infusion, which means it’s delivered directly into a vein. The typical administration schedule is:

  • Given on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle
  • The infusion usually takes 2-10 minutes
  • The starting dose is often 20 mg/m² (milligrams per square meter of body surface area)
  • If well-tolerated, the dose may be increased to 27 mg/m² or higher in subsequent cycles

Treatment typically continues for up to 12 cycles, but this can vary depending on how well the patient responds and tolerates the medication.[1]

Carfilzomib Combination Therapies

Carfilzomib is often used in combination with other medications to enhance its effectiveness. Common combination therapies include:

  • Carfilzomib, Lenalidomide, and Dexamethasone (KRd): This combination is used for patients who have received at least one prior treatment.[4]
  • Carfilzomib and Dexamethasone (Kd): This two-drug combination is another option for previously treated patients.[4]
  • Carfilzomib, Cyclophosphamide, and Dexamethasone (CCyd): This combination has been studied in newly diagnosed multiple myeloma patients.[2]
  • Carfilzomib, Pomalidomide, and Dexamethasone (CPd): This combination has been investigated for relapsed or refractory multiple myeloma.[5]

Effectiveness of Carfilzomib

Clinical trials have shown that carfilzomib can be effective in treating multiple myeloma, particularly in patients who have not responded to other treatments. Key measures of effectiveness include:

  • Overall Response Rate (ORR): This measures how many patients have a significant reduction in their cancer. In some studies, the ORR for carfilzomib was around 24% in heavily pre-treated patients.[6]
  • Progression-Free Survival (PFS): This is the length of time during and after treatment that a patient lives without the cancer getting worse. Carfilzomib has shown improvements in PFS in various studies.[1]
  • Overall Survival (OS): This measures how long patients live after starting treatment. Some studies have shown improvements in OS with carfilzomib-based regimens.[1]

Potential Side Effects

Like all medications, carfilzomib can cause side effects. Some of the potential side effects include:

  • Fatigue: Feeling very tired is a common side effect.
  • Anemia: A decrease in red blood cells, which can cause fatigue and shortness of breath.
  • Nausea and vomiting
  • Diarrhea
  • Shortness of breath: Some patients may experience dyspnea (difficulty breathing).[4]
  • Thrombocytopenia: A decrease in platelets, which can increase the risk of bleeding.
  • Peripheral neuropathy: Numbness, tingling, or pain in the hands and feet.

It’s important to report any side effects to your healthcare team, as they can often be managed with supportive care or adjustments to your treatment plan.[7]

Aspect Details
Primary Indications Multiple Myeloma (relapsed/refractory), Hematologic Malignancies
Other Potential Indications Solid Tumors, Neuroendocrine Cancers
Administration Intravenous infusion, typically over 2-30 minutes
Dosing Range 20 mg/m² to 56 mg/m², depending on study protocol and patient tolerance
Treatment Schedule Usually administered on specific days within 28-day cycles
Key Outcomes Measured Overall Response Rate (ORR), Progression-Free Survival (PFS), Safety Profile
Special Populations Studied Patients with renal insufficiency, hepatic impairment
Common Side Effects Fatigue, nausea, shortness of breath, fever, low blood cell counts
Ongoing Research Focus Optimal dosing, combination therapies, efficacy in various cancer types

FAQ

  • What is carfilzomib and how does it work? Carfilzomib is a proteasome inhibitor used to treat multiple myeloma and other cancers. It works by blocking the proteasome, a cellular structure that breaks down proteins, leading to the accumulation of proteins in cancer cells and causing them to die.
  • What types of cancer is carfilzomib being studied for? Carfilzomib is primarily being studied for multiple myeloma, including relapsed and refractory cases. It is also being investigated for other hematologic malignancies, solid tumors, and neuroendocrine cancers.
  • How is carfilzomib administered in clinical trials? Carfilzomib is typically administered intravenously (IV) over 2-30 minutes, depending on the study protocol. The dosing schedule usually involves administration on specific days within 28-day cycles, with doses ranging from 20 mg/m² to 56 mg/m².
  • What are some common side effects of carfilzomib? Common side effects of carfilzomib may include fatigue, nausea, shortness of breath, fever, and low blood cell counts. Some patients may also experience peripheral neuropathy, which is numbness or tingling in the hands and feet.
  • Can patients with kidney or liver problems receive carfilzomib? Clinical trials are investigating the use of carfilzomib in patients with varying degrees of kidney and liver function. These studies aim to determine the appropriate dosing and safety profile for patients with renal or hepatic impairment.

Ongoing Clinical Trials on Carfilzomib

  • Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Czechia Germany Greece Italy The Netherlands +2

  • Study on Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed High-Risk Multiple Myeloma Patients

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Germany

  • Study on Early Treatment for Multiple Myeloma Relapse Using Carfilzomib, Bortezomib, Daratumumab, Lenalidomide, and Dexamethasone in Patients with MRD Negativity

    Not recruiting

    4 1 1 1
    Investigated drugs:
    Lithuania Norway

  • Study on KRd Consolidation for Multiple Myeloma Patients with Positive PET-CT: Carfilzomib, Lenalidomide, and Dexamethasone Treatment

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Denmark Norway

  • Study on Alnuctamab and Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +8

  • Study on Isatuximab, Carfilzomib, and Dexamethasone for Adults with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Czechia Greece Portugal

  • Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +7

  • Study Comparing bb2121 with Standard Treatments for Patients with Relapsed and Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Norway +1

  • Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +7

  • Study on Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed, Refractory, or Newly Diagnosed Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Denmark France Germany Greece Italy Spain

Glossary

  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell that produces antibodies to fight infections.
  • Relapsed Multiple Myeloma: Multiple myeloma that has returned after a period of improvement following treatment.
  • Refractory Multiple Myeloma: Multiple myeloma that does not respond to treatment or stops responding after initially improving.
  • Proteasome Inhibitor: A type of drug that blocks the action of proteasomes, cellular structures responsible for breaking down proteins, leading to the accumulation of proteins in cancer cells and causing cell death.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it worsening.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Hepatic Impairment: Reduced liver function that can affect how drugs are processed and eliminated from the body.
  • Renal Insufficiency: Decreased kidney function that can impact how drugs are filtered and excreted from the body.
  • Neuroendocrine Cancer: A type of cancer that begins in specialized cells called neuroendocrine cells, which have traits of both nerve cells and hormone-producing cells.

References

  1. https://clinicaltrials.gov/study/NCT00511238
  2. https://clinicaltrials.gov/study/NCT01346787
  3. https://clinicaltrials.gov/study/NCT01351623
  4. https://clinicaltrials.gov/study/NCT04004338
  5. https://clinicaltrials.gov/study/NCT02185820
  6. https://clinicaltrials.gov/study/NCT02056756
  7. https://clinicaltrials.gov/study/NCT05675449